ATE511644T1 - Neues screening-verfahren - Google Patents

Neues screening-verfahren

Info

Publication number
ATE511644T1
ATE511644T1 AT04702440T AT04702440T ATE511644T1 AT E511644 T1 ATE511644 T1 AT E511644T1 AT 04702440 T AT04702440 T AT 04702440T AT 04702440 T AT04702440 T AT 04702440T AT E511644 T1 ATE511644 T1 AT E511644T1
Authority
AT
Austria
Prior art keywords
seq
salt
screening process
new screening
same
Prior art date
Application number
AT04702440T
Other languages
English (en)
Inventor
Yasuaki Ito
Ryo Fujii
Shuji Hinuma
Shoji Fukusumi
Minoru Maruyama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE511644T1 publication Critical patent/ATE511644T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
AT04702440T 2003-01-17 2004-01-15 Neues screening-verfahren ATE511644T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003010001 2003-01-17
JP2003104540 2003-04-08
JP2003194497 2003-07-09
JP2003329080 2003-09-19
PCT/JP2004/000248 WO2004065960A1 (ja) 2003-01-17 2004-01-15 新規スクリーニング方法

Publications (1)

Publication Number Publication Date
ATE511644T1 true ATE511644T1 (de) 2011-06-15

Family

ID=32777143

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04702440T ATE511644T1 (de) 2003-01-17 2004-01-15 Neues screening-verfahren

Country Status (4)

Country Link
US (1) US20080160033A1 (de)
EP (1) EP1584925B1 (de)
AT (1) ATE511644T1 (de)
WO (1) WO2004065960A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
EP1731602B1 (de) * 2004-03-01 2010-03-31 Pharmafrontier Co., Ltd. Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels
EP1932920A4 (de) * 2005-09-02 2009-04-08 Eisai R&D Man Co Ltd Screening-verfahren für eine gegen krankheit wirksame substanz unter verwendung von gpr120 und phospholipase
WO2007134613A1 (en) * 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
EP2151236A4 (de) 2007-04-26 2013-01-16 Japan Science & Tech Agency G-protein-konjugierter rezeptoragonist
GB201310664D0 (en) 2013-06-14 2013-07-31 Mars Inc Feline taste receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000611A2 (en) 1998-06-30 2000-01-06 Millennium Pharmaceuticals, Inc. 14273 receptor, a g-protein coupled receptor
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
US6395877B1 (en) * 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US20020151705A1 (en) * 1999-10-05 2002-10-17 Smith Kelli E. DNA encoding orphan SNORF49 receptor
JP2001211885A (ja) * 2000-02-02 2001-08-07 Kyowa Hakko Kogyo Co Ltd 新規ポリペプチド
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
AU2002258428A1 (en) 2001-02-26 2002-09-12 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
WO2002088182A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Nouvelle proteine des recepteurs couples aux proteines-g et adn associe
US7214495B2 (en) * 2002-02-14 2007-05-08 Takeda Pharmaceutical Company Limited Screening method

Also Published As

Publication number Publication date
EP1584925A4 (de) 2006-09-06
EP1584925A1 (de) 2005-10-12
US20080160033A1 (en) 2008-07-03
WO2004065960A1 (ja) 2004-08-05
EP1584925B1 (de) 2011-06-01

Similar Documents

Publication Publication Date Title
ATE466030T1 (de) Neues screening-verfahren
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
DE60224536D1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
DE602005009856D1 (de) Verfahren zur reinigung von fsh
EP1147123A4 (de) Neuartige geruchsrezeptoren in drosophila
EP1584925A4 (de) Neues screening-verfahren
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
ATE494550T1 (de) Neues screening-verfahren
WO2003021262A1 (fr) Procede de criblage
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
WO2003082320A1 (fr) Nouveau procede de criblage
ATE445159T1 (de) Neues screening-verfahren
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
DE602004016006D1 (de) Screening-verfahren
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
DE60323052D1 (de) Zwei gonadotropin-freisetzende hormone und methode zur isolierung
ATE556135T1 (de) Neues protein
WO2003060516A1 (en) Screening method
DE60302911D1 (de) Verfahren zur Herstellung von Alkyl-Harnstoffen aus O,S-Dimethyl-dithiocarbonaten
ATE491472T1 (de) Verfahren zur verringerung von depressionen durch hemmung der wirkung des kalziumkanals vom n-typ
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
DK1401871T3 (da) Immunologisk bindingsmolekyle, der hæmmer den syncytiale fusion af trophoblastceller
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
SE9902763D0 (sv) Novel receptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties